Effectiveness of a nurse-led one-to-one education programme in addition to standard care in children with atopic dermatitis: a multicentre randomized control trial.


Journal

The British journal of dermatology
ISSN: 1365-2133
Titre abrégé: Br J Dermatol
Pays: England
ID NLM: 0004041

Informations de publication

Date de publication:
12 Jun 2024
Historique:
received: 12 06 2023
revised: 08 03 2024
medline: 12 6 2024
pubmed: 12 6 2024
entrez: 12 6 2024
Statut: aheadofprint

Résumé

Therapeutic patient education (TPE) is recommended for children with atopic dermatitis (AD), but no consensus has been reached on the optimal tailoring of delivery. While repeated multidisciplinary group education sessions have shown effectiveness, the benefits of one-on-one educational interventions led by nurses for children with AD have not yet been assessed. To assess the benefits of additional, well-structured, 1-h nurse-led individual TPE interventions in children with AD and their families compared with standard care alone. Children with moderate-to-severe AD and their parents were randomized to receive a 1-h nurse-led education session in addition to standard care vs. standard care alone. The primary outcome was the area under the curve (AUC) of the SCORing of Atopic Dermatitis index (SCORAD) from baseline to week 24 (lower AUC values represent better long-term control of the disease). In our study, 176 patients were randomized across 11 centres, and 153 were included in the full analysis set. The mean (SD) age was 4.47 (4.57) years. By week 24, there were no significant differences in the AUCs of the SCORAD between the two groups (P = 0.3). Secondary outcomes including patient-reported severity and quality of life [AUCs of the patient-oriented SCORAD (PO-SCORAD) and Infants' Dermatitis Quality of Life Index (IDLQI), Children's Dermatitis Quality of Life Index (CDLQI) and Family Dermatitis Quality of Life Index (FDLQI)] were not significantly different between the two groups. The only significant change observed in the intervention group, when compared with the one receiving standard care, was a decrease in topical steroid phobia, as assessed by the topical corticosteroid phobia (TOPICOP) score. Prespecified subgroup analyses showed that disease severity in the intervention group was significantly lower throughout the study, compared with the standard-care group when participants had moderate AD at baseline (n = 47); while participants with severe AD at baseline (n = 106) did not show benefit from the intervention. Participants showed no additional benefit from the intervention regardless of age group. This study did not show any additional effectiveness, in long-term severity control, of a 1-h nurse-led TPE intervention in children with AD treated with standard care, compared with those treated with standard care alone. However, it should be noted that the intervention reduced the fear of using topical steroids and may be beneficial for patients in the subgroup with moderate AD.

Sections du résumé

BACKGROUND BACKGROUND
Therapeutic patient education (TPE) is recommended for children with atopic dermatitis (AD), but no consensus has been reached on the optimal tailoring of delivery. While repeated multidisciplinary group education sessions have shown effectiveness, the benefits of one-on-one educational interventions led by nurses for children with AD have not yet been assessed.
OBJECTIVES OBJECTIVE
To assess the benefits of additional, well-structured, 1-h nurse-led individual TPE interventions in children with AD and their families compared with standard care alone.
METHODS METHODS
Children with moderate-to-severe AD and their parents were randomized to receive a 1-h nurse-led education session in addition to standard care vs. standard care alone. The primary outcome was the area under the curve (AUC) of the SCORing of Atopic Dermatitis index (SCORAD) from baseline to week 24 (lower AUC values represent better long-term control of the disease).
RESULTS RESULTS
In our study, 176 patients were randomized across 11 centres, and 153 were included in the full analysis set. The mean (SD) age was 4.47 (4.57) years. By week 24, there were no significant differences in the AUCs of the SCORAD between the two groups (P = 0.3). Secondary outcomes including patient-reported severity and quality of life [AUCs of the patient-oriented SCORAD (PO-SCORAD) and Infants' Dermatitis Quality of Life Index (IDLQI), Children's Dermatitis Quality of Life Index (CDLQI) and Family Dermatitis Quality of Life Index (FDLQI)] were not significantly different between the two groups. The only significant change observed in the intervention group, when compared with the one receiving standard care, was a decrease in topical steroid phobia, as assessed by the topical corticosteroid phobia (TOPICOP) score. Prespecified subgroup analyses showed that disease severity in the intervention group was significantly lower throughout the study, compared with the standard-care group when participants had moderate AD at baseline (n = 47); while participants with severe AD at baseline (n = 106) did not show benefit from the intervention. Participants showed no additional benefit from the intervention regardless of age group.
CONCLUSIONS CONCLUSIONS
This study did not show any additional effectiveness, in long-term severity control, of a 1-h nurse-led TPE intervention in children with AD treated with standard care, compared with those treated with standard care alone. However, it should be noted that the intervention reduced the fear of using topical steroids and may be beneficial for patients in the subgroup with moderate AD.

Identifiants

pubmed: 38863109
pii: 7691316
doi: 10.1093/bjd/ljae111
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : French Ministry of Solidarities and Health
ID : PHRCN-14-0204

Informations de copyright

© The Author(s) 2024. Published by Oxford University Press on behalf of British Association of Dermatologists. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.

Déclaration de conflit d'intérêts

Conflicts of interest S.B. declares payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events and support for attending meetings and/or travel from AbbVie, Alexion, Almirall, AstraZeneca, Chiesi, Eli Lilly, Galderma, Janssen, LEO Pharma, Novartis, Pfizer, Sanofi-Genzyme and UCB Pharma. H.A. declares consulting fees from Abbvie, BMS, Lilly, Novartis and Sanofi; payment of honoraria from AbbVie, Lilly, Novartis, Pierre Fabre, Sanofi and UCB; and support for attending meetings from AbbVie and Almirall. N.R.-P. declares support for attending meetings and/or travel from Sanofi-Genzyme.

Auteurs

Sebastien Barbarot (S)

Department of Dermatology, Nantes Université, CHU Nantes, INRAE, UMR 1280, PhAN, Nantes, France.
Departments of Dermatology, Nantes Université, CHU Nantes, Nantes, France.

Helene Aubert (H)

Departments of Dermatology, Nantes Université, CHU Nantes, Nantes, France.

Marie-Anne Vibet (MA)

Research and Innovation Department, Nantes Université, CHU Nantes, Nantes, France.

Maëlle Leray (M)

Research and Innovation Department, Nantes Université, CHU Nantes, Nantes, France.

Aurore Foureau (A)

Departments of Dermatology, Nantes Université, CHU Nantes, Nantes, France.

Francoise Elan (F)

Departments of Dermatology, Nantes Université, CHU Nantes, Nantes, France.

Laëtitia Menneron (L)

Departments of Dermatology, Nantes Université, CHU Nantes, Nantes, France.

Jean-Francois Stalder (JF)

Departments of Dermatology, Nantes Université, CHU Nantes, Nantes, France.

Alice Phan (A)

Department of Dermatology, CHU Lyon, Lyon, France.

Catherine Droitcourt (C)

Department of Dermatology, CHU Rennes, Rennes, France.

Anne-Claire Bursztejn (AC)

Department of Dermatology, CHRU Nancy, Vandoeuvre-lès-Nancy, France.

Franck Boralevi (F)

Department of Dermatology, CHU Bordeaux, Talence, France.

Christine Chiaverini (C)

Department of Dermatology, CHU Nice, Nice, France.

Nadia Raison-Peyron (N)

Department of Dermatology, CHU Montpellier, Montpellier, France.

Audrey Lasek (A)

Department of Dermatology, Saint Vincent de Paul Hospital, GHICL, Lille, France.

Laurent Misery (L)

Department of Dermatology, CHRU Brest, Brest, France.

Claire Abasq (C)

Department of Dermatology, CHRU Brest, Brest, France.

Stephanie Mallet (S)

Department of Dermatology, APHM, Marseille, France.

Classifications MeSH